Search Results
Your search for ,New matches 16916 pages
Showing 5651 - 5700Beyond BROCADE3: Just the Beginning for Veliparib-Based Therapy in Advanced BRCA-Mutated Breast Cancer
As recently reported in The Lancet Oncology and reviewed in the October 10, 2020, issue of The ASCO Post, the phase III BROCADE3 trial has shown that the addition of veliparib to carboplatin and paclitaxel improved progression-free survival in previously treated BRCA-mutated advanced breast...
An Emergency Room Physician Explores Her Own Healing Through a Life of Medical Service
Medical memoir dramas, especially those centered in the emergency room (ER), are often met with the anticipation of top-rated medical shows portrayed on TV, in which there is nonstop blood-and-guts action and sizzling tensions between shouting doctors and nurses. In her recently published memoir,...
Three New Transatlantic Research Teams to Study Difficult-to-Treat Childhood Cancers
Although remarkable progress has been made in advancing pediatric cancer research, critical unmet needs remain, especially for more aggressive cancers such as neuroblastomas and Ewing sarcoma. The Stand Up To Cancer–Cancer Research UK Pediatric Cancer New Discoveries Challenge has awarded three...
ASTRO Honors 2020 Gold Medalists
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2020 Gold Medal awards and other honors at the 62nd ASTRO Annual Meeting, which was held online due to the COVID-19 pandemic. ASTRO Gold Medal Bruce Haffty, MD, FASTRO, and Brian O’Sullivan, MD, FASTRO, were each...
Expert Point of View: Charles L. Shapiro, MD
The ASCO Post asked Charles L. Shapiro, MD, Professor of Medicine, Director of Translational Breast Cancer Research, and Director of Cancer Survivorship at Icahn School of Medicine at Mount Sinai, New York, for his thoughts on the exploratory analysis of PALOMA-3. He first pointed out that the...
Using Meaning-Centered Interventions to Address Suffering on the Cancer Journey
A large body of research has shed light on how the cancer experience and related losses often leave patients and their families struggling to find a sense of meaning in their lives.1-7 The COVID-19 pandemic has amplified these difficulties, as meaningful activities and experiences have been...
ACCC Statement on Rise of Cancer Mortality and Advanced Cancer Rates in 2020
Randall A. Oyer, MD, President of the Association of Community Cancer Centers (ACCC), released a statement regarding the rise in mortality rates of specific cancers and the rise in the occurrence of advanced metastatic cancers in 2020. New research presented at the United European Gastroenterology ...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
OneOncology Launches Community Oncology Research Network
OneOncology, a partnership of independent oncology practices, has announced the formation of a separate subsidiary, the OneOncology Research Network (OneR). The new platform is a national nonexclusive clinical trial site management organization that will enhance the current research programs...
Committed to Excellence: Oncology Drug Development Marches on Amid a Pandemic
Instituted as part of the 21st Century Cures Act, the Oncology Center of Excellence (OCE) fosters a unified interaction between three U.S. Food and Drug Administration (FDA) centers: Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and...
Medical Financial Hardship: Pervasive and Possibly Linked to Mortality Among Patients With Cancer
Reducing the financial impact of cancer diagnosis and treatment may save not only bank accounts but lives as well, according to recent data. Two separate survey studies presented during the 2020 ASCO Quality Care Symposium have highlighted the pervasiveness and deadliness of financial toxicity,...
After Leaving His Home in Syria to Train Abroad, an Oncologist Makes a Tough Decision to Return
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nedal Estfan, MD, a noted Syrian oncologist who was at the forefront of his county’s earliest efforts to establish a national cancer care system during a time of political and military turmoil....
Chronic Lymphocytic Leukemia: New Treatments Achieve Deeper Remissions
At the National Comprehensive Cancer Network® (NCCN®) 2020 Virtual Congress: Hematologic Malignancies, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, reviewed current data on chronic lymphocytic leukemia (CLL), including promising new combinations of modern...
CURE Media Group Announces Recipients of 2020 Lung Cancer Heroes Award
The CURE Media Group, a multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, recently announced four recipients of the inaugural 2020 Lung Cancer Heroes awards and the recipient of the Lifetime Achievement award. The 2020 Lung Cancer Heroes are:...
Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), but there may be newer strategies that can produce equivalent outcomes, and not all patients with...
Results From ASCO’s 2020 National Cancer Opinions Survey
As in past years, the results from ASCO’s 2020 National Cancer Opinions Survey showed a startling dichotomy in the perceptions of Americans on a variety of health-care issues. As expected, the two major events this year, the COVID-19 pandemic and a national reckoning over racial injustice,...
Lung Cancer: Precision Therapies at the Forefront
What a difference 20 years have made! In the year 2000, the results of the ECOG 1594 trial were reported at the plenary session of the ASCO Annual Meeting. The study demonstrated comparable outcomes between four different platinum-based chemotherapy regimens for the treatment of metastatic...
NCCN Announces Beth Gaffney, MBA, as New Vice President of U.S. and Global Business Development
The National Comprehensive Cancer Network (NCCN) announced the appointment of Beth Gaffney, MBA, as the new Vice President of U.S. and Global Business Development. In this role, Ms. Gaffney will oversee both U.S. and global business activities and the development of the NCCN brand worldwide. Ms....
After Surgery for Colorectal Cancer, Intensive Monitoring of Little Benefit: PRODIGE 13
Is intensive monitoring of patients after curative colorectal cancer resection warranted? Not necessarily, according to the findings of PRODIGE 13, reported at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.1 “After curative surgery, the addition of CEA [carcinoembryonic...
Richard Pazdur, MD, Awarded the Simon M. Shubitz Cancer Prize and Lectureship
For more than 4 decades, the University of Chicago Cancer Research Foundation’s Simon M. Shubitz Cancer Prize and Lectureship has honored an internationally renowned individual for his or her exceptional contributions to cancer research and clinical care. The recipient of this year’s award is...
Expert Point of View: Amy Tiersten, MD and Erika Hamilton, MD
Sharing their thoughts on KEYNOTE-355 were Amy Tiersten, MD, Professor of Medicine at Icahn School of Medicine at Mount Sinai, New York, and Erika Hamilton, MD, Director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute/Tennessee Oncology, Nashville, who presented...
First-Line Pembrolizumab Delays Disease Progression in PD-L1–Expressing Metastatic Triple-Negative Breast Cancer
In the phase III KEYNOTE-355 trial, pembrolizumab combined with several chemotherapy partners yielded a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with previously untreated locally advanced or metastatic...
FDA Expands Approval of Companion Diagnostic for Olaparib in Prostate Cancer
On November 9, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic for olaparib. As a companion diagnostic, FoundationOne Liquid CDx will use a blood-based biopsy to identify patients with BRCA1, BRCA2, and/or ATM alterations and...
CancerCare Welcomes J. Leonard Lichtenfeld, MD, MACP, to Board of Trustees
CancerCare, a leading national nonprofit organization providing free support services to anyone affected by cancer, welcomed new board member J. Leonard (Len) Lichtenfeld, MD, MACP, who most recently served as Deputy Chief Medical Officer for the American Cancer Society at its global headquarters...
LUNGevity Launches New Lung Cancer Advocacy Program
LUNGevity Foundation, the nation’s leading lung cancer–focused nonprofit organization, recently announced the launch of the LUNGevity Action Network, a new engagement program that enables lung cancer advocacy at many levels. The Action Network empowers advocates to engage in awareness and policy...
Cancer in Older Adults: The History of Geriatric Oncology, Part 3
In the preceding two issues of The ASCO Post, we explored the overall history of geriatric oncology from 1980 to 2020. In this concluding part of the series, we focus on the invaluable contributions made by oncology nurses to the field. Over the past several decades, geriatric oncology has...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer
As reported inThe New England Journal of Medicine by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues and by Lori J. Wirth, MD, of Massachusetts General Hospital, and colleagues, the phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase ...
AACI President Knudsen to Focus 2-Year Term on Mitigating Health Disparities
Karen E. Knudsen, MBA, PhD, is the new President of the Association of American Cancer Institutes (AACI). She began her 2-year term at the close of the virtual 2020 AACI/Cancer Center Administrators Forum (CCAF) Annual Meeting. A member of AACI’s Board of Directors since 2016, Dr. Knudsen chaired ...
Huntsman Cancer Institute Names New Chief Academic Officer and Senior Director of Basic Science
Huntsman Cancer Institute (HCI) at the University of Utah recently announced leadership appointments for two long-standing cancer center members. Brad Cairns, PhD, has accepted an appointment as Chief Academic Officer at HCI, and Alana Welm, PhD, has accepted an appointment as Senior Director of...
FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers
On October 27, 2020, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
Avelumab Maintenance Therapy Improves Overall Survival in Advanced or Metastatic Urothelial Carcinoma
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III JAVELIN Bladder 100 trial found that maintenance treatment with avelumab plus best supportive care significantly improved overall survival...
Expert Point of View: Andreas du Bois, MD, PhD
The invited discussant of the phase III INOVATYON trial was Andreas du Bois, MD, PhD, Chairman of the Department of Gynecology and Gynecologic Oncology at Kliniken Essen Mitte, Germany, and Chairman of the AGO Study Group. As Dr. du Bois explained, the study “dealt with an old question: Does...
Reducing Symptomatic Toxicity Burden in Older Patients With Advanced Cancer Via Geriatric Assessment
As the number of older patients with cancer continues to rise, interventions that reduce the high rates of symptoms, toxicity, and distress in this population are urgently needed. Research presented during the 2020 ASCO Quality Care Symposium has added to the growing body of evidence supporting...
Biomarker-Driven Master Protocol to Test Therapies for Previously Treated Patients With Squamous NSCLC
In an article published in The Lancet Oncology, Redman et al described the conduct of and findings from the Lung Cancer Master Protocol (Lung-MAP; SWOG S1400), a completed biomarker-driven master protocol designed to address the need for improved therapies for previously treated patients with...
FDA Pipeline: Priority Reviews in NSCLC, Gastric Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to a PD-1 inhibitor for the treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC), and also granted Priority Review to a HER2-directed antibody-drug conjugate for patients with...
Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events
Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizumab. A genome-wide association study—according to researchers, the largest such study in patients...
Extended Follow-up of KEYNOTE-426: First-Line Pembrolizumab/Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib in the first-line treatment of advanced renal cell...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Checkpoint Inhibitor and Chemotherapy Combinations Fail to Move Bar as First-Line Therapy for Advanced Urothelial Cancer
Two different phase III studies found that combining an anti–PD-1/PD-L1 checkpoint inhibitor (pembrolizumab in KEYNOTE-361) with platinum-based chemotherapy or with another checkpoint inhibitor (the anti–CTLA-4 antibody tremelimumab in DANUBE) failed to significantly improve overall or...
Study Finds Universal Genetic Testing Uncovers More Inherited Mutations vs Guideline-Based Genetic Testing
Universal genetic testing may uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, and strengthen the use of precision medicine. In a new study published by N. Jewel Samadder, MD, and colleagues in JAMA Oncology, researchers conducted genetic testing in...
Are Neighborhood Poverty, Public Insurance Linked to Poorer Outcomes in Children With Cancer Undergoing Stem Cell Transplant?
Despite the increasing use of hematopoietic stem cell transplant as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children who undergo a transplant for cancer may be more likely to die of treatment-related complications if they live in...
Expert Point of View: Ana Oaknin, MD, PhD
The innovaTV 204 trial’s invited discussant, Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology in Barcelona, was encouraged by the study’s findings. “Of note, the response rate was 24%, the time to response was short, and the median duration of...
Novel Treatments Show Activity in Advanced Cervical Cancer
The treatment of recurrent or metastatic cervical cancer has not changed much in recent years, but according to preliminary trials presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, checkpoint inhibitors and antibody-drug conjugates may become new options. In the...
Breast Cancer Risk and Disease-Causing Genetic Mutations in Women Older Than 65
Women with breast cancer onset after age 65 often do not qualify for genetic testing, yet little is known about the frequency of disease-causing mutations in breast cancer predisposition genes in this population. In a new study, researchers investigated the prevalence of disease-causing variants in ...
Should Patients With a Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Also Undergo Surgery?
A nonsurgical treatment option for rectal cancer that preserves quality of life may be safe for selected patients, according to a new study comparing it with standard surgical treatment. These findings were published by Beard et al in the Journal of the American College of Surgeons and were...
Development of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer
As reported in JAMA Oncology, Dess et al have developed a novel clinical prognostic stage group system for nonmetastatic prostate cancer that “meets criteria set forth by the American Joint Committee on Cancer [AJCC] Precision Medicine Core committee… [and outperforms] the existing [AJCC] system...
First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
In an Italian phase II trial (GIMEMA LAL2116) reported in The New England Journal of Medicine, Foà et al found that first-line induction and consolidation treatment with dasatinib plus blinatumomab produced a high rate of molecular response in adults with Philadelphia chromosome–positive acute...
Time at Home vs in Health-Care Institutions for Older Patients After Cancer Surgery
In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that older patients undergoing surgery for cancer were likely to spend a high number of days at home vs in health-care institutions in the years following surgery for cancer, suggesting favorable functional...
